Literature DB >> 33757384

Prolongation of allograft survival by artemisinin treatment is associated with blockade of OX40-OX40L.

Lihua Liu1, Juanzhi Zhao2, An Li3, Xuan Yang3, Ben Sprangers4, Shengqiao Li3,5.   

Abstract

OBJECTIVES: It has been demonstrated that artemisinin (ART) possesses multiple immune modulatory effects. However, its role as immunosuppressant in allogeneic transplantation is undetermined. Here, we investigated the effect of ART on co-stimulatory signaling in OX40+ T cells and evaluated ART as a potential immunosuppressant in transplantation.
MATERIALS AND METHODS: Allogeneic skin transplantation was performed in C57BL/6 to BALB/c mice. Recipient mice were administrated with vehicle, ART or cyclosporine A daily from day 0 to day 19 post transplantation. Proportions of splenic CD4+OX40+ and CD4+CD44hiCD62Lhi cells, and serum IgG was measured by using flow cytometry. An in vitro lymphocyte stimulation with Con A or LPS under various concentrations of ART was performed, expression of CD4+OX40+ and CD4+CD44hiCD62Lhi cells was evaluated, and interleukin(IL)-6 production was measured by ELISA.
RESULTS: In in vivo allogeneic skin transplant model, ART significantly prolongs allogeneic skin survival. Furthermore, our in vitro studies demonstrate that the immune suppression of ART on T cells is associated with a reduction in OX40+ T cells and inhibition of IL-6 secretion.
CONCLUSION: Our data indicate that the OX40-OX40L pathway and IL-6 are possibly involved in ART-induced immunosuppression, and ART is a potential novel immunosuppressant.

Entities:  

Keywords:  Artemisinin; IL-6; OX40; allogeneic transplantation; memory T cells

Mesh:

Substances:

Year:  2021        PMID: 33757384     DOI: 10.1080/08923973.2021.1902347

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN: 0892-3973            Impact factor:   2.730


  1 in total

Review 1.  Immunoregulation by Artemisinin and Its Derivatives: A New Role for Old Antimalarial Drugs.

Authors:  Feifei Qiu; Junfeng Liu; Xiumei Mo; Huazhen Liu; Yuchao Chen; Zhenhua Dai
Journal:  Front Immunol       Date:  2021-09-09       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.